

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :	A1	(11) International Publication Number: WO 98/50051
A61K 33/32, 33/24, 33/36, 33/04, 33/06, 35/78, 31/70, 31/51, 31/44, 31/355, 31/34, 31/07		(43) International Publication Date: 12 November 1998 (12.11.98)

(21) International Application Number: PCT/US97/07122	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 5 May 1997 (05.05.97)	<b>Published</b> <i>With international search report.</i>

(54) Title: TREATMENT OF SICKLE CELL DISEASE, TREATMENT OF IMMUNE SYSTEM DISEASES AND OTHER DISEASES NORMALLY ASSOCIATED WITH SICKLE CELL ANEMIA

(57) Abstract

A maintenance regimen with controlled intake of particular vitamin, mineral, and micronutrient formulations, drastically reduces the incidence and severity of sickle cell disease crises. The formulations include vitamin A, vitamin B-1, vitamin B-2, vitamin B-6, vitamin B-12, vitamin C, vitamin D, vitamin E, niacinamide, para-aminobenzoic acid (PABA), pantothenic acid, choline bitartrate, inositol, rutin, citrus bioflavonoid complex, betaine hydrochloride, hesperidin complex, folic acid, biotin, calcium, iron, magnesium, zinc, potassium, manganese, iodine, chromium, selenium, and a pharmaceutically acceptable carrier, provided at or just below critical saturation levels, determined for each individual by carefully monitoring tolerance on titration. The daily dose may exceed that necessary as dietary or nutritional supplements, and trigger an increase in the production of viable hemoglobin, and alters the overall blood profile. Platelet concentration is increased up to twice that seen in normal blood, and the red blood cells produced display increased resistance to sickling. This enhanced biosynthesis is achieved by providing sufficient stores of precursors that stimulate low level manufacture without substantial feedback control by the upper central nervous system.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**TREATMENT OF SICKLE CELL DISEASE**  
**TREATMENT OF IMMUNE SYSTEM DISEASES AND OTHER DISEASES**  
**NORMALLY ASSOCIATED WITH SICKLE CELL ANEMIA**

**BACKGROUND OF THE INVENTION**

**1. FIELD OF THE INVENTION**

**CONTINUATION IN PART OF PATENT SERIAL NO. 08/516,737**  
**FILED ON 18 AUGUST 1995**

The present invention is a continuation of the inventors first patent and relates to the treatment and prophylaxis of hemoglobin disorders and extends that treatment to the problems associated with the immune system failures and organ failures that occur along with sickle cell anemia. More particularly, the present invention provides a tailored preventative and/or maintenance treatment regimen for an individual suffering from genetic sickle cell disease or immune system failures for other reasons. This particular invention is specifically directed at treating organ failures and infections that occur in sickle cell anemia and suggest that the treatment may be used in conditions like AIDS, Diabetes, Lupus and other conditions with similar problems.

**2. DESCRIPTION OF THE PRIOR ART**

As described in NIH Publication No. 89-2117, "Management and Therapy of Sickle Cell Disease," 1989, herein incorporated, sickle cell disease is a generic term for a group of genetic disorders characterized by the predominance of hemoglobin S (Hb S). These disorders include sickle cell anemia, the sickle beta thalassemia syndromes, and hemoglobinopathies in which Hb S is in association with another abnormal hemoglobin.

The two beta globulin genes located on chromosome 11 and the four alpha globulin genes located on chromosome 16 determine hemoglobin production. Normal red blood cells are produced

in individuals who carry all four alpha globin genes and two normal beta globin genes ( $\beta$ A). Carriers of the sickle cell trait, who do not normally physically express the disease, have a normal beta globin gene and a  $\beta$ S globin gene, resulting in the production of both normal hemoglobin A and hemoglobin S, with a predominance of Hb A. Individuals who are homozygous for the sickle beta globin gene ( $\beta$ S) have sickle cell anemia (Hb SS). Individuals with sickle beta thalassemia have a  $\beta$ S gene and a gene for beta thalassemia,  $\beta$ thal. Those who have two abnormal beta globin genes,  $\beta$ S and  $\beta$ C, produce hemoglobins Hb S and Hb C, and have Hb SC disease. The absence of two of the alpha globin genes results in alpha thalassemia. Abnormalities in both the beta and alpha genes may be present in the same individual.

Red blood cells of sufferers of sickle cell disease are prone to distortions in geometry when deoxygenated. This distortion arises from the polymerization or gelling of Hb S molecules into elongated microtubular structures. Hb S is more susceptible to polymerization in the deoxygenated state than hemoglobin A due to the substitution of a hydrophobic residue valine for a polar residue glutamic acid in Hb A. These distortions of red blood cells, or sickling, leads to chronic hemolytic anemia and vaso-occlusion resulting in ischemic tissue injury.

Hemolytic anemia is caused by abnormal properties of Hb S and/or by repeated cycles of sickling and unsickling, which interact to produce irreversible red cell membrane changes and erythrocyte destruction. Tissue injury is usually produced by hypoxia secondary to obstruction of blood vessels by an accumulation of sickled erythrocytes. The organs at greatest risk are those with venous sinuses where blood flow is slow and oxygen tension and pH are low (spleen, kidney, bone marrow) or those with a limited terminal arterial blood supply (eye, head of the femur). Symptoms of the hypoxic injury may be either acute (e.g., painful events, acute chest syndrome) or insidious in onset (e.g., aseptic necrosis of the hips, sickle cell retinopathy). The effects of acute and chronic tissue injury may ultimately result in organ failure, particularly as the patient ages.

In managing chronic sickle cell disease, conventional maintenance measures usually include preventative administration of antibiotics, hydration, and supplementation of dietary deficiencies. For painful events, analgesics such as aspirin, acetaminophen, ibuprofen, codeine or oxycodone may be administered. More drastic measures, such as blood transfusions or the use of compositions which change the geometry and/or oxygen binding ability of sickled red blood cells have been employed for acute indications.

The use of various vitamins, minerals, and amino acids in treating anemia related disorders has been the subject of earlier patents. For example, US Patent No. 4,945,083, issued July 31, 1990 to Christian Jansen, Jr. describes a method for treating or preventing macrocytic-megaloblastic anemias with multi-factor vitamin formulations. US Patent No. 4,261,980, issued May 14, 1981 to Joseph Cort and US Patent No. 4,376,766, issued March 15, 1983 to Rosalind Collinson-Jones et al. describe the use of amino acids in sickle cell treatments.

Other combination therapies for sickle cell anemia with formulations that include vitamins are described in US Patent No. 4,904,678, issued February 27, 1990 to Oji Chima, and US Patent No. 5,108,754, issued April 28, 1992 to Michael Wilburn. US Patent No. 4,866,052, issued September 12, 1989 to Robert Hider et al. describes the use of zinc bound to various ligands, including ascorbic acid (vitamin C).

US Patent No. 5,114,972, issued May 19, 1992 to Tsuyoshi Ohnishi describes the anti-oxidant and anti-cancer activity of prostaglandin derivatives of ascorbic acid. US Patent No. 4,629,625, issued December 16, 1986 to Gerald Gaull describes compositions including vitamins and/or minerals in combination with taurine, a compound synthesized in animal tissues, useful in providing a protective action on cell membranes. US Patent No. 5,364,644, issued November 15, 1994 to Zbigniew Walaszek et al. describes methods for lowering cholesterol with D-glucarate which may include a multiplicity of vitamins, minerals, and micronutrients.

None of the above inventions and patents, taken either singly or in combination, is seen to describe the instant invention as claimed.

## SUMMARY OF THE INVENTION

The present invention is based on the finding that a maintenance regimen with controlled intake of particular vitamin, mineral, and micronutrient formulations, drastically reduces the incidence and severity of sickle cell disease crises. The formulations useful in the present invention include vitamin A, vitamin B-1, vitamin B-2, vitamin B-6, vitamin B-12, vitamin C, vitamin D, vitamin E, niacinamide, para-aminobenzoic acid (PABA), pantothenic acid, choline bitartrate, inositol, rutin, citrus bioflavonoid complex, betaine hydrochloride, hesperidin complex, folic acid, biotin, calcium, iron, magnesium, zinc, potassium, manganese, iodine, chromium, selenium, and a pharmaceutically acceptable carrier.

These vitamins and minerals are administered at or just below critical saturation levels which may be determined for each individual by establishing a base line dosage level of multiple vitamins and minerals over a period of days; adjusting this base line dosage upwards until the manifestation of easily observed responses; and finally reducing the dosage slightly until such manifestations disappear. Accordingly, the daily doses for some of these vitamins, minerals, and micronutrients will exceed those conventionally considered necessary as dietary or nutritional supplements.

The present method triggers an increase in the production of viable hemoglobin, and alters the overall blood profile. Platelet concentration is increased up to about twice that observed in normal blood, and the red blood cells produced display increased resistance to sickling. This enhanced biosynthesis is achieved by providing sufficient stores of precursors that stimulate low level manufacture without substantial feedback control by the upper central nervous system.

Accordingly, it is a principal object of the invention to provide a treatment for sickle cell anemia and related disorders with a composition that includes multiple vitamins and minerals.

It is another object of the invention to provide an approach to treatment wherein dosage is critically controlled based on close monitoring of expressed responses for each individual.

It is a further object of the invention to provide a treatment regimen which may be administered in the home environment without expensive equipment.

These and other objects of the present invention will become readily apparent upon further review of the following specification.

**DETAILED DESCRIPTION OF THE INVENTION**

The present invention provides a method of treating persons having sickle cell disease however the treatment is not limited to persons with sickle cell anemia. While this treatment has been tested and proven to be effective in persons with sickle cell anemia, the process was designed to work as a immune system enhancement. The dosage range specified below is the range found to be effective in persons with sickle cell anemia. Persons with AIDS, and other type deficiencies will have different ranges and those ranges will have to be established through additional test. The effective daily dosage at saturation of each vitamin or mineral falls within the following ranges for persons with sickle cell anemia:

Vitamin A	8,250-250,000 I.U.
Vitamin B-1	25-1000 mg.
Vitamin B-2	25-1000 mg.
Vitamin B-6	25-1000 mg.
Vitamin B-12	25-1000 mcg.
Vitamin C	25-1000 mg.
Vitamin D	100-4000 I.U.
Vitamin E	25-1000 I.U.
Niacinamide	25-1000 mg.
Para-aminobenzoic acid (PABA)	25-1000 mg.
Pantothentic Acid	25-1000 mg.
Choline Bitartrate	25-1000 mg.
Inositol	25-1000 mg.
Rutin	8.25-250 mg.
Citrus Bioflavonoid Complex	8.25-250 mg.
Betaine Hydrochloride	8.25-250 mg.
Hesperidin Complex	1.25-50 mg.
Folic Acid	100-4000 mcg.
Biotin	25-1000 mcg.
Calcium	10-400 mg.
Iron	8.25-250 mg.

Magnesium	5-100 mg.
Zinc	5-100 mg.
Potassium	3.75-150 mg.
Manganese	1.5-60 mg.
Iodine	37.5-1500 mcg.
Chromium	3.75-150 mcg.
Selenium	2.5-100 mcg.

It is preferable to more closely tailor the present method to a particular individual, to insure that saturation levels are administered and maintained. Conventionally employed determinations of dosage based on body weight may be unreliable in providing the necessary dosage, as each individual responds at different dosages uncorrelated with weight. However, age, and disease may be used to select a useful starting point for determining an effective daily dosage level.

The description of the practice of this method of treatment for persons with sickle cell anemia is used because it is the disease with which there is the most test. This method of treatment was originally designed to be effective in diabetes. Future test in these areas are being done and are giving positive results. The method described below are the same in all general terms in other conditions.

The normal range of conditions for body surface temperature, frequency of urination, sleep and physical activity should be established prior to practicing the present method. Persons of six years of age or younger, with the disease of sickle cell, should start with the minimum dosage listed above, those of from 7-15 years of age, twice that amount, and those over 15 years of age four times that amount. This selected base daily dosage is administered for an initial period of from 3-10 days, and the conditions established for the person are monitored. Deviations outside the established range for these conditions indicate that saturation has been surpassed, and the dosage should be reduced, preferably by up to half.

After this initial period, the base daily dosage may be gradually adjusted upward to a modified daily dosage with each succeeding 3-10 day period, in increments of from about 1 to about 100 percent, if the above noted conditions stay within the normal range established. Should the conditions in any period deviate outside the established range, a downward adjustment of about 1 to 50 percent should be made. Preferably, the relative proportions of these components is maintained as

the dosage is increased or decreased.

In particular, an increase in urination rate to twice normal, loss of sleep, marked hyperactivity, and/or a perceptible increase in the body surface temperature of the skin to the touch without any systemic fever indicate that the saturation level has been surpassed. Though a brightening of the eyes is a normal effect of the present inventive method, and overnight loss of tint in the whites of the eyes during the initial period or any subsequent period may be also used as an indication to reduce the dosage.

The increments chosen for each succeeding modified daily dosage should be reduced until a first modified daily dosage is found, in which no deviation of conditions outside the normal range is perceived. The first modified daily dosage is within from about 1 to 10 percent of a second modified dosage in which conditions deviate beyond normal. At that point, the fist modified daily dosage is selected and used for continuous administration.

Sustained-release formulations of the above ingredients, such as polymer matrix tablets, liquid gel compositions, sprays and powders may be used, and are ideally suited for maintaining a dosage at or near saturation level, once determined. These formulations may include an inert pharmaceutically acceptable carrier. Preferably, the carrier is a base selected from one or more of rice, papaya, water crest, parsley, kelp, alfalfa, cabbage, cherry, wheat flower, or bromelain. It should be noted that powders seem to perform the least and seems to sometimes gives false indications. Sprays are being tested for immediate relief. The very best performer is Sustained release a second best are gel forms.

Mineral ingredients are preferably provided as amino acid chelates. Trace amounts of additional chelate materials may also be present, including actinium, aluminum, antimony, barium, beryllium, bismuth, boron, bromine, cadmium, cerium, cesium, chlorine, cobalt, copper, dysprosium, erbium, europium, fluorine, gadolinium, gallium, germanium, gold, hafnium, holmium, indium, iridium, lanthanum, lithium, lutetium, molybdenum, neodymium, nickel, niobium, osmium, palladium, phosphorous, platinum, praseodymium, rhenium, rhodium, rubidium, ruthenium, samarium, scandium, silicon, silver, sodium, strontium, sulfur, tantalum, tellurium, terbium, thallium, thorium, tin, titanium, tungsten, uranium, vanadium, ytterbium, yttrium, and zirconium.

To assist in determining and administering the saturation level dosage to a person having sickle cell disease, a kit may be used that includes individual tablets or capsules each with the

minimum amounts, or integer factor thereof, of the vitamins, minerals, and micronutrients, already in combination, and in a suitable pharmaceutical carrier. For insuring proper monitoring of the present process, forms and/or charts may be provided that include space for recordation of conditions at associated daily doses. This kit may further include detailed instructions for carrying out the present method in any appropriate media, as well as any information regarding the formulation.

The administration of a daily saturation dosage when continuously maintained provides an effective sickle cell crisis preventative measure that may be practiced outside a critical care environment. This allows persons suffering from sickle cell disease to lead more productive, normal lives. The constant threat of crisis onset is dramatically reduced, thereby contributing to greater mental and emotional confidence.

The exact pharmacodynamic and/or biochemical mechanisms by which the present method is effective have not been established. However, a clearly observed increase in the production of viable hemoglobin and platelets indicates that a low level adjustment in blood cell production is triggered as the saturation level is approached. The oxygen carrying capacity of the blood per volume is accordingly increased, and sickle cell crises based on oxygen deficiencies are substantially eliminated. In addition, the immune system is significantly enhanced, thereby reducing the need for additional medication, such as antibiotics and analgesics, normally used in sickle cell disease management.

When the daily saturation level is exceeded, however, these positive effects were observed to be substantially reduced. An upper CNS feedback response may be indicated for this edge phenomena, and should be avoided. It is therefore a critical aspect of the present invention to maintain the fine balance at or just below a daily saturation level.

#### EXAMPLE

A patient diagnosed with Sickle Cell Anemia was treated with conventional methods including the use of transfusions, antibiotics, acetaminophen, and codeine. Despite these treatments sickle cell crises were frequent, resulting in hospitalizations for severe fevers and multiple organ failures.

At age 7, all conventional treatments were ceased, and an experimental daily dosage "A" was established according to the present invention, monitoring hyperactivity, urination rate, eye color,

and body temperature. Sickle cell crises were drastically reduced and no hospitalizations were required while the present method was practiced. The daily dosages were periodically re-evaluated, and adjusted. Dosages "B" and "C" were the levels established at ages 13 and 18, respectively.

<u>Component</u>	<u>Dosage A</u>	<u>Dosage B</u>	<u>Dosage C</u>
Vitamin A	1.5 mg.	3.0 mg.	4
Vitamin B-1	50.0 mg.	100.0 mg.	150
Vitamin B-2	50.0 mg.	100.0 mg.	150
Vitamin B-6	50.0 mg.	100.0 mg.	150
Vitamin B-12	0.05 mg.	0.10 mg.	0.
Vitamin C	50.0 mg.	100.0 mg.	150
Vitamin D	0.012 mg.	0.025 mg.	0.03
Vitamin E	43.4 mg.	86.7 mg.	130
Niacinamide	50.0 mg.	100.0 mg.	150
Para-aminobenzoic acid	50.0 mg.	100.0 mg.	150
Pantothenic Acid	50.0 mg.	100.0 mg.	150
Choline Bitartrate	50.0 mg.	100.0 mg.	150
Inositol	50.0 mg.	100.0 mg.	150
Rutin	12.5 mg.	25.0 mg.	37
Citrus Bioflavonoid Complex	12.5 mg.	25.0 mg.	37
Betaine Hydrochloride	12.5 mg.	25.0 mg.	37
Hesperidin Complex	2.5 mg.	5.0 mg.	7
Folic Acid	0.2 mg.	0.4 mg.	0
Biotin	0.05 mg.	0.10 mg.	0.
Calcium	10.0 mg.	20.0 ,g.	30
Iron	12.5 mg.	25.0 mg.	37
Magnesium	10.0 mg.	20.0 mg.	30
Zinc	10.0 mg.	20.0 mg.	30
Potassium	7.5 mg.	15.0 mg.	22
Manganese	3.0 mg.	6.1 mg.	9
Iodine	0.075 mg.	0.15 mg.	0.
Chromium	0.0075 mg.	0.015 mg.	0.0
Selenium	0.005 mg.	0.01 mg.	0.0

At age 14, this daily dosage regimen was temporarily interrupted under medical direction, and conventional treatment was reinstated. Within a four days, sickle cell crises returned in a frequency and at a level of severity at least as great as encountered before age 7, resulting in retinal detachment, and the loss of one of the patient's eyes. Conventional treatment was again ceased and experimental daily dosage "B" was administered. Again, sickle cell crises were drastically reduced and no additional hospitalizations were required while practicing the present regimen. There was no more organ failures, only one infection, no pneumonia, or any of the conditions that were previously associated with this condition. In addition the person has been able to participate in exercises and dance competitions. In addition she has taken flight lessons with no apparent problems. She has been able to perform as though the disease no longer existed within her while on this regiment. All symptoms of the disease disappears while on this regiment.

It is to be understood that the present invention is not limited to the embodiments described above, but encompasses any and all embodiments within the scope of the following claims.

**CLAIMS**

Claim # 1.

1. A method for treating or preventing sickle cell crises in a person having sickle cell disease which comprises administering to said person a cumulative daily dosage of from about 8,250 to 250,000 I.U. vitamin A; from about 25 to 1000 mg. each of vitamin B-1, vitamin B-2, vitamin B-6, vitamin C, niacinamide, para-aminobenzoic acid, pantothenic acid, choline bitartrate, and inositol; from about 25 to 1000 mcg. each of vitamin B-12 and biotin; from about 100 to 4000 I.U. of vitamin D; from about 100 to 4000 mcg. of folic acid; from about 25 to 1000 I.U. of vitamin E; from about 8.25 to 250 mg. each of rutin, citrus bioflavonoid complex, betaine hydrochloride, and iron; from about 1.25 to 50 mg. of hesperidin complex, from about 10 to 400 mg. of calcium; from about 5 to 100 mg. of magnesium; from about 5 to 100 mg. of zinc; from about 3.75 to 150 mg. of potassium; from about 1.5 to 60 mg. of manganese; from about 37.5 to 1500 mcg. of iodine; from about 3.75 to 150 mcg. of chromium; and from 2.5 to 100 mcg. of selenium.

2. The method according to claim 1, wherein said cumulative daily dosage is supplied in the form of sustained-release pharmaceutical compositions consisting essentially of from about 8,250 to 250,000 I.U. vitamin A; from about 25 to 1000 mg. each of vitamin B-1, vitamin B-2, vitamin B-6, vitamin C, niacinamide, para-aminobenzoic acid, pantothenic acid, choline bitartrate, and inositol; from about 25 to 1000 mcg. each of vitamin B-12 and biotin; from about 100 to 4000 I.U. of vitamin D; from about 100 to 4000 mcg. of folic acid; from about 25 to 1000 I.U. of vitamin E; from about 8.25 to 250 mg. each of rutin, citrus bioflavonoid complex, betaine hydrochloride, and iron; from about 1.25 to 50 mg. of hesperidin complex, from about 10 to 400 mg. of calcium; from about 5 to 100 mg. of magnesium; from about 5 to 100 mg. of zinc; from about 3.75 to 150 mg. of potassium; from about 1.5 to 60 mg. of manganese; from about 37.5 to 1500 mcg. of iodine; from about 3.75 to 150 mcg. of chromium; from 2.5 to 100 mcg. of selenium; and a pharmaceutically acceptable carrier.

3. The method according to claim 2, wherein said composition is administered substantially at a daily saturation dosage, wherein said daily saturation dosage is determined by additional preliminary steps of:

a) establishing a normal range for at least one condition selected from the group consisting of frequency of urination, sleep, physical activity, and combinations thereof, for said person;

- b) selecting a base daily dosage of a composition consisting essentially of vitamin A, vitamin B-1, vitamin B-2, vitamin B-6, vitamin B-12, vitamin C, vitamin D, vitamin E, niacinamide, para-aminobenzoic acid (PABA), pantothenic acid, choline bitartrate, inositol, rutin, citrus bioflavonoid complex, betaine hydrochloride, hesperidin complex, folic acid, biotin, calcium, iron, magnesium, zinc, potassium, manganese, iodine, chromium, selenium, and a pharmaceutically acceptable carrier;
- c) administering to said person having sickle cell disease said base daily dosage for an initial period of from about three to about ten days;
- d) continuously monitoring said condition of said person;
- e) adjusting said daily dosage upward in increments of from about 1 to 100 percent if said monitoring reveals no deviation of conditions outside the established normal range, and downward by increments of from 1 to 50 percent if said monitoring reveals a perceptible deviation of conditions outside the established normal range, thereby establishing a modified daily dosage;
- f) administering to said person having sickle cell disease said modified daily dosage for an additional period of from about 3 to about 10 days;
- g) repeating steps d) - f), decreasing succeeding adjusted increments, until a first modified daily dosage in which monitoring reveals no deviation of conditions outside the normal range and a second modified dosage in which monitoring reveals deviation of conditions outside the normal range are within from about 1 to 10 percent of each other; and
- h) selecting said first modified daily dosage as said daily saturation dosage.

4. The method according to claim 3, wherein the daily saturation dosage is provided in at least one unit dose of said sustained release composition, each said unit dose containing from 8,250 to 25,000 I.U. vitamin A; from about 25 to 100 mg. each of vitamin B-1, vitamin B-2, vitamin B-6, vitamin C, niacinamide, para-aminobenzoic acid, pantothenic acid, choline bitartrate, and inositol; from about 25 to 100 mcg. each of vitamin B-12 and biotin; from about 100 to 400 I.U. of vitamin D; from about 100 to 4000 mcg. of folic acid; from about 25 to 100 I.U. of vitamin E; from about 8.25 to 25 mg. each of rutin, citrus bioflavonoid complex, betaine hydrochloride, and iron; from about 1.25 to 5 mg. of hesperidin complex, from about 10 to 40 mg. of calcium; from about 5 to 10 mg. of magnesium; from about 5 to 10 mg. of zinc; from about 3.75 to 15 mg. of potassium; from about 1.5

to 6 mg. of manganese; from about 37.5 to 150 mcg. of iodine; from about 3.75 to 15 mcg. of chromium; and from 2.5 to 10 mcg. of selenium.

5. A kit for carrying out the method of claim 4, comprising a multiplicity of said unit dose; means for recordation of conditions and daily dosages; and instructions detailing said method.

**Claim # 2.**

A method for treating and preventing organ failures in a person having sickle cell disease which comprises administering to said person cumulative daily dosage of from about 8,250 to 250,000 I.U. vitamin A; from about 25 to 1000 mg. each of vitamin B-1, vitamin B-2, vitamin B-6, vitamin C, niacinamide, para-aminobenzoic acid, pantothenic acid, chorine bitartrate, and inositol; from about 25 to 1000 mcg. each of vitamin B-12 and biotin; from about 100 to 4000 I.U. of vitamin D; from about 100 to 4000 mcg. of folic acid; from about 25 to 1000 I.U. of vitamin E; from about 8.25 to 250 mg. each of rutin, citrus bioflavonoid complex, betaine hydrochloride, and iron; from about 1.25 to 50 mg. of hesperidin complex, from about 10 to 400 mg. of calcium; from about 5 to 100 mg. of magnesium; from about 5 to 100 mg. of zinc; from about 3.75 to 150 mg. of potassium; from about 1.5 to 60 mg. of manganese; from about 37.5 to 1500 mcg. of iodine; from about 3.75 to 150 mcg. of chromium; and from 2.5 to 100 mcg. of selenium and a pharmaceutically acceptable carrier.

The method of treating organ failures are the same as treating sickle cell anemia as set out in claim I section 1-5 in this application.

**Claim # 3.**

A method for treating and preventing organ failures in a person having other conditions not related to sickle cell anemia, which comprises administering to said person cumulative daily dosage of from about 8,250 to 250,000 I.U. vitamin A; from about 25 to 1000 mg. each of vitamin B-1, vitamin B-2, vitamin B-6, vitamin C, niacinamide, para-aminobenzoic acid, pantothenic acid, choline bitartrate, and inositol; from about 25 to 1000 mcg. each of vitamin B-12 and biotin; from about 00 to 4000x5449Y1

E; from about 8.25 to 250 mg. each of rutin, citrus bioflavonoid complex, betaine hydrochloride, and iron; from about 1.25 to 50 mg. of hesperidin complex, from about 10 to 400 mg. of calcium; from

about 5 to 100 mg. of magnesium; from about 5 to 100 mg. of zinc; from about 3.75 to 150 mg. of potassium; from about 1.5 to 60 mg. of manganese; from about 37.5 to 1500 mcg. of iodine; from about 3.75 to 150 mcg. of chromium; and from 2.5 to 100 mcg. of selenium and a pharmaceutically acceptable carrier.

The method of treating organ failures are the same as treating sickle cell anemia as set out in claim I section 1-5 in this application.

**Claim # 4.**

A method for treating and preventing infections in a person having sickle cell anemia and other conditions not related to sickle cell anemia, which comprises administering to said person cumulative daily dosage of from about 8,250 to 250,000 I.U. vitamin A; from about 25 to 1000 mg. each of vitamin B-1, vitamin B-2, vitamin B-6, vitamin C, niacinamide, para-aminobenzoic acid, pantothenic acid, choline bitartrate, and inositol; from about 25 to 1000 mcg. each of vitamin B-12 and biotin; from about 100 to 4000 I.U. of vitamin D; from about 100 to 4000 mcg. of folic acid; from about 25 to 1000 I.U. of vitamin E; from about 8.25 to 250 mg. each of rutin, citrus bioflavonoid complex, betaine hydrochloride, and iron; from about 1.25 to 50 mg. of hesperidin complex, from about 10 to 400 mg. of calcium; from about 5 to 100 mg. of magnesium; from about 5 to 100 mg. of zinc; from about 3.75 to 150 mg. of potassium; from about 1.5 to 60 mg. of manganese; from about 37.5 to 1500 mcg. of iodine; from about 3.75 to 150 mcg. of chromium; and from 2.5 to 100 mcg. of selenium and a pharmaceutically acceptable carrier.

The method of treating infections are the same as treating sickle cell anemia as set out in claim I section 1-5 in this application.

**Claim # 5.**

A method for treating and preventing pneumonia in a person having sickle cell anemia and other conditions not related to sickle cell anemia, which comprises administering to said person cumulative daily dosage of from about 8,250 to 250,000 I.U. vitamin A; from about 25 to 1000 mg. each of vitamin B-1, vitamin B-2, vitamin B-6, vitamin C, niacinamide, para-aminobenzoic acid, pantothenic acid, choline bitartrate, and inositol; from about 25 to 1000 mcg. each of vitamin B-12 and biotin; from about 100 to 4000 I.U. of vitamin D; from about 100 to 4000 mcg. of folic acid; from about 25

to 1000 I.U. of vitamin E; from about 8.25 to 250 mg. each of rutin, citrus bioflavonoid complex, betaine hydrochloride, and iron; from about 1.25 to 50 mg. of hesperidin complex, from about 10 to 400 mg. of calcium; from about 5 to 100 mg. of magnesium; from about 5 to 100 mg. of zinc; from about 3.75 to 150 mg. of potassium; from about 1.5 to 60 mg. of manganese; from about 37.5 to 1500 mcg. of iodine; from about 3.75 to 150 mcg. of chromium; and from 2.5 to 100 mcg. of selenium and a pharmaceutically acceptable carrier.

The method of treating pneumonia are the same as treating sickle cell anemia as set out in claim I section 1-5 in this application.

#### Claim # 6.

A method for treating and preventing pneumonia in a person having sickle cell anemia and other conditions not related to sickle cell anemia, which comprises administering to said person cumulative daily dosage of from about 8,250 to 250,000 I.U. vitamin A; from about 25 to 1000 mg. each of vitamin B-1, vitamin B-2, vitamin B-6, vitamin C, niacinamide, para-aminobenzoic acid, pantothenic acid, choline bitartrate, and inositol; from about 25 to 1000 mcg. each of vitamin B-12 and biotin; from about 100 to 4000 I.U. of vitamin D; from about 100 to 4000 mcg. of folic acid; from about 25 to 1000 I.U. of vitamin E; from about 8.25 to 250 mg. each of rutin, citrus bioflavonoid complex, betaine hydrochloride, and iron; from about 1.25 to 50 mg. of hesperidin complex, from about 10 to 400 mg. of calcium; from about 5 to 100 mg. of magnesium; from about 5 to 100 mg. of zinc; from about 3.75 to 150 mg. of potassium; from about 1.5 to 60 mg. of manganese; from about 37.5 to 1500 mcg. of iodine; from about 3.75 to 150 mcg. of chromium; and from 2.5 to 100 mcg. of selenium and a pharmaceutically acceptable carrier.

The method of treating pneumonia are the same as treating sickle cell anemia as set out in claim I section 1-5 in this application.

#### Claim # 7

A method for treating and preventing a unknown, life threatening illness in a person having sickle cell anemia and other conditions not related to sickle cell anemia, which comprises administering to said person cumulative daily dosage of from about 8,250 to 250,000 I.U. vitamin A; from about 25 to 1000 mg. each of vitamin B-1, vitamin B-2, vitamin B-6, vitamin C, niacinamide,

para-aminobenzoic acid, pantothenic acid, choline bitartrate, and inositol; from about 25 to 1000 mcg. each of vitamin B-12 and biotin; from about 100 to 4000 I.U. of vitamin D; from about 100 to 4000 mcg. of folic acid; from about 25 to 1000 I.U. of vitamin E; from about 8.25 to 250 mg. each of rutin, citrus bioflavonoid complex, betaine hydrochloride, and iron; from about 1.25 to 50 mg. of hesperidin complex, from about 10 to 400 mg. of calcium; from about 5 to 100 mg. of magnesium; from about 5 to 100 mg. of zinc; from about 3.75 to 150 mg. of potassium; from about 1.5 to 60 mg. of manganese; from about 37.5 to 1500 mcg. of iodine; from about 3.75 to 150 mcg. of chromium; and from 2.5 to 100 mcg. of selenium and a pharmaceutically acceptable carrier.

The method of treating unknown life threatening illnesses are the same as treating sickle cell anemia as set out in claim I section 1-5 in this application.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/07122

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 33/32, 33/24, 33/36, 33/04, 33/06, 35/78, 31/70, 31/51, 31/44, 31/355, 31/34, 31/07  
 US CL :424/667, 682, 702, 195.1, 514/52, 276, 345, 356, 458, 474, 725

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/667, 682, 702, 195.1, 514/52, 276, 345, 356, 458, 474, 725

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Chemical Abstracts

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,866,052 A (HIDER et al) 12 September 1989, see entire document.	1-7
A	US 4,904,678 A (CHIMA) 27 February 1990, see entire document.	1-7
A	US 5,108,754 A (WILBURN) 28 April 1992, see entire document.	1-7
A	US 5,114,972 A (OHNISHI) 19 May 1992, see entire document.	1-7
A	US 5,364,644 A (WALASZEK et al) 15 November 1994, see entire document.	1-7

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
18 JULY 1997	29 AUG 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer  JAMES H REAMER <i>[Signature]</i> Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet)(July 1992)★